Regeneron to Buy 23andMe Out of Bankruptcy
Digest more
Top News
Overview
Impacts
Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer consumer DNA testing services.
Regeneron Pharmaceuticals is set to acquire substantially all assets of 23andMe for $256 million. The deal is expected to close in Q3 2025
The pharmaceutical giant plans to continue offering 23andMe’s DNA testing service and pledged to adopt its privacy practices to protect customer data.
Regeneron is buying the assets of 23andMe, which filed for Chapter 11 bankruptcy in March after facing a series of hurdles including a data breach.
Being spliced on to Regeneron will free the genetic testing company from its fatal dependence on sporadic revenue
Explore more
What happened to 23andMe? Here's a look at its history from launch to bankruptcy and acquisition by Regeneron.
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.